Both eribulin and nab-paclitaxel are widely used and effective chemotherapy agents for metastatic breast cancer; however, their predictive factors remain unknown. The usefulness of the neutrophil-to-lymphocyte ratio (NLR) in terms of treatment efficacy was investigated. We observed that a low NLR at baseline might be a significant indicator of improved outcomes for patients treated with eribulin but not with nab-paclitaxel. Introduction: Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-tolymphocyte ratio (NLR) is a significant prognostic factor for early-stage breast cancer, we investigated its usefulness in terms of the eribulin or nab-paclitaxel treatment efficacy for MBC. Patients and Methods: A total of 85 patients with MBC treated with eribulin (n ¼ 59) or nab-paclitaxel (n ¼ 26) were recruited. NLR values were collected at baseline, after 1 cycle, after 2 cycles, and at the end of treatment. The NLR cutoff value was set at 3. Results: The progression-free survival (PFS) of patients with an NLR < 3 at baseline (median, 242 days; n ¼ 24) was significantly better than that of patients with an NLR of ! 3 (median, 98 days; n ¼ 35; hazard ratio, 0.37, 95% confidence interval, 0.18-0.71; P ¼ .0032). Similarly, the overall survival was marginally significantly better in patients with an NLR < 3 who were treated with eribulin (P ¼ .058). However, the NLR was not significantly associated with PFS or overall survival for patients treated with nab-paclitaxel. No significant association was found between the NLR during treatment and PFS in the eribulin group. The significance of the NLR for the efficacy of eribulin was consistent, irrespective of estrogen receptor status, previous anthracycline or endocrine use, and the number of previous chemotherapy regimens. Conclusion: A low NLR at baseline was significantly associated with improved PFS in patients treated with eribulin but not in those treated with nab-paclitaxel. Therefore, the baseline NLR might be clinically useful for selecting patients who would benefit from eribulin.
Introduction
Although both eribulin and nab-paclitaxel are widely used effective chemotherapy agents for locally advanced or metastatic breast cancers (MBC), their predictive factors remain unknown. Eribulin is a synthetic macrocyclic ketone analog of halichondrin B that inhibits the synthesis of microtubule polymerization. 1, 2 In the EMBRACE (eribulin monotherapy vs. treatment of physician's choice in patients with metastatic breast cancer) trial, the treatment efficacy of eribulin monotherapy was compared with that of the treatment of the physicians' choice in 762 patients with heavily pretreated MBC. 3 Although no statistically significant difference was found in progression-free survival (PFS), the overall survival (OS) of patients assigned to receive eribulin (median, 13.1 months) was significantly better than that for those assigned to receive treatment of the physicians' choice (10.6 months; hazard ratio [HR] , 0.81; 95% confidence interval [CI] , 0.66-0.99; P ¼ .041). Similarly, no statistically significant difference was seen in PFS between MBC patients treated with eribulin and those treated with capecitabine (HR, 1.08; 95% CI, 0.93-1.25; P ¼ .30). However, the OS for the eribulin group was marginally improved compared with that of the capecitabine group (HR, 0.88; 95% CI, 0.77-1.00; P ¼ .056). 4 The effect on OS induced by eribulin has been further demonstrated in real-world data. In estrogen receptor-positive (ER þ )/human epidermal growth factor receptor 2-negative (HER2 À ) MBC, the OS of patients who received eribulin (n ¼ 66) was significantly better than that of patients treated with conventional chemotherapy regimens (n ¼ 227; HR, 0.67; 95% CI, 0.47-0.96; P ¼ .025). 5 In addition, in a pooled analysis of data from 1644 patients, a significantly superior OS was consistently observed in the eribulin group (n ¼ 946) compared with that of the comparators (n ¼ 698; HR, 0.85; 95% CI, 0.76-0.94; P ¼ .002). 6 The improved eribulin treatment efficacy was also observed in the subset of patients with triple-negative (TN) breast cancer (ER À , progesterone receptor
], HER2 À ), those with nonvisceral metastasis, and those with > 2 organs involved. 6, 7 Thus, eribulin is thought to be superior in these types of MBC subgroups; however, the biomarkers of treatment efficacy for eribulin have not yet been determined. The results from in vitro and in vivo studies have shown that eribulin suppresses the epithelialemesenchymal transition (EMT) and induces the mesenchymaleepithelial transition (MET), resulting in a lower potential for metastasis. 8 In addition, eribulin enhances reoxygenation by increasing blood perfusion in the tumor through vasculature remodeling and reduces plasma concentrations of transforming growth factor-b, an EMT inducer. 9, 10 Because reoxygenation downregulates hypoxia-inducible factor-1a, 11, 12 the MET seems to be generated directly, as well as indirectly mediated, through vascular remodeling by eribulin. The weakened malignant potential through MET with eribulin treatment might be in line with the prolonged survival benefit. Recently, Kashiwagi et al 13 reported that among the TN subset of MBC patients treated with eribulin, the PFS of patients with high frequencies of tumorinfiltrating lymphocytes (TILs) was significantly better than that of patients with low frequencies (P ¼ .033). These data might indicate that the prolonged treatment efficacy induced by eribulin stems, at least in part, from an immune reaction. In addition to TILs, the neutrophil-to-lymphocyte ratio (NLR), a marker of systemic immunity, has been demonstrated to be a significant prognostic factor for early-stage breast cancer. 14, 15 However, to the best of our knowledge, the usefulness of the NLR in terms of the efficacy of MBC treatment has yet to be reported. To identify an immune-related biomarker for the treatment efficacy of eribulin, we investigated the usefulness of the NLR in patients with MBC treated with eribulin or nab-paclitaxel.
Materials and Methods

Patient Eligibility
A total of 85 patients with MBC treated with eribulin (n ¼ 59) or nab-paclitaxel (n ¼ 26) at Hyogo College of Medicine from November 2010 to September 2017 were recruited for the present retrospective study. All participants were confirmed to have primary breast cancer through histologic examination, and locally advanced stage or metastasis was confirmed through diagnostic radiography using computed tomography, whole-body bone scintigraphy, or 2-[(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography. Of the 85 patients, the HER2 status was positive in 4, unknown in 1, and negative in the remaining 80 patients (Table 1) . One male breast cancer patient was included. All patients were treated with either eribulin or nab-paclitaxel monotherapy. Those patients who received combination therapy with other chemotherapy agents, anti-HER2 therapy, or endocrine therapy were excluded except, for those treated with concurrent use of zoledronic acid (n ¼ 31) or denosumab (n ¼ 16). Zoledronic acid, followed by denosumab, was administered to 3 patients. The patients were eligible if they had received > 1 cycle of chemotherapy.
Eribulin and Nab-Paclitaxel Chemotherapy Schedules
Eribulin was administered intravenously at 1.4 mg/m 2 over 5 minutes on days 1 and 8 of each 21-day cycle. If adverse events occurred, the dose was reduced to 1.1 or 0.7 mg/m 2 . For patients with a decreased neutrophil count, the administration was delayed. For nab-paclitaxel, 260 mg/m 2 was administered intravenously over 30 minutes every 3 weeks and was reduced to 220 or 180 mg/m 2 for patients who required a dose reduction or delayed administration. The chemotherapy regimens were continued until disease progression (n ¼ 61) or the appearance of intolerable adverse events (n ¼ 14), with treatment ongoing for 10 patients at the last followup visit. The median duration of eribulin and nab-paclitaxel treatment was 106 and 111.5 days, respectively. The median number of previous chemotherapy regimens was 2 (range, 0-7) for the eribulin group and 1 (range, 0-5) for the nab-paclitaxel group. Previous anthracycline and taxane exposure was reported for 52.5% and 83.1% of patients in the eribulin group and 38.5% and 46.2% of patients in the nab-paclitaxel group, respectively ( Table 1) .
Measurements of NLR and Patient Outcomes
The neutrophil and lymphocyte counts were measured automatically using Sysmex XN-9000 or XN-1000 hematology analyzers (Sysmex Corp, Kobe, Japan). The absolute numbers of neutrophils were calculated using stab plus segment fractions. The NLR for each patient was calculated by dividing the number of neutrophils by the number of lymphocytes. The NLR was determined at baseline, after 1 cycle, after 2 cycles, and at the end of treatment (after the last cycle). The NLR cutoff value was set at 3 in accordance with previous studies. 15, 16 We evaluated PFS, defined as the duration from the start to the end of each treatment because of disease progression or death from any cause. OS was calculated from the start of each treatment to death from any cause. Visceral disease included the development of metastases to the lungs (n ¼ 40), liver (n ¼ 35), brain (n ¼ 5), or stomach (n ¼ 1). Other metastases, including bone (n ¼ 61), lymph node (n ¼ 48), and local (n ¼ 29), were defined as nonvisceral.
The ethics committee of the Hyogo College of Medicine approved the present study (approval no. 1969), which was performed in accordance with the Declaration of Helsinki. Because the present study collected only retrospective clinical data and offered no risk to the participants, their written informed consent was not required.
Statistical Analysis
Kaplan-Meier plots of PFS and OS for the different groups were compared using log-rank tests. Univariable and multivariable analyses of clinicopathologic factors and the NLR for PFS were performed using a Cox proportional hazards model to obtain the HRs and 95% CIs. The relationships between the clinicopathologic characteristics and NLRs were evaluated using the c 2 or Fisher exact test, as appropriate. Statistical significance was set at P < .05, and One male patient each was included in the nab-paclitaxel and eribulin groups.
b Treatment was ongoing for 9 patients in the eribulin group and 1 patient in the nab-paclitaxel group at the latest follow-up point.
Low NLR and Improved PFS the statistical calculations were performed using JMP Pro, version 12 (SAS Institute Inc, Cary, NC).
Results
Clinicopathologic Characteristics of Eribulin and NabPaclitaxel Groups
In the present study, 59 and 26 patients were included in the eribulin and nab-paclitaxel groups, respectively. In the eribulin and nab-paclitaxel group, 78.0% and 61.5% had ER þ cancer, respectively (Table 1) . Except for 3 patients in the eribulin group and 2 patients in the nab-paclitaxel group, all the patients had HER2
À breast cancer. Patients with PR þ breast cancer were significantly more prevalent in the eribulin group (54.2%) than in the nabpaclitaxel group (26.9%; P ¼ .033). In contrast to the nabpaclitaxel group (46.2%), most patients in the eribulin group (83.1%) had previously received a taxane (P ¼ .0012). In the eribulin group, 88.0% of patients stopped treatment because of disease progression. In contrast, 32.0% of patients receiving nab-paclitaxel discontinued treatment because of adverse events (P ¼ .057). No statistically significant difference was found between the eribulin and nab-paclitaxel groups in the neutrophil (P ¼ .345) or lymphocyte (P ¼ .523) counts or the NLR (P ¼ .155).
Relationship Between NLR and Patient Prognosis
Using the cutoff NLR of 3, we compared the PFS of patients treated with eribulin or nab-paclitaxel according to the NLR (Figure 1 ). The PFS for the patients in the eribulin group with an NLR < 3 (median, 242 days; n ¼ 24) was significantly better than that of those with an NLR of ! 3 (median, 98 days; n ¼ 35; HR, 0.37; 95% CI, 0.18-0.71; P ¼ .0032; Figure 1A ). In contrast, no significant association was found between the NLR and PFS in the nab-paclitaxel group (P ¼ .84; Figure 1B ). Similar to PFS, the OS for patients in the eribulin group with an NLR of < 3 (median, 821 days; n ¼ 24) was marginally significantly better than that of those with an NLR ! 3 (median, 372 days; n ¼ 35; HR, 0.44; 95% CI, 0.17-1.01; P ¼ .058; Figure 1C) ; however, no significant association was found between the NLR and OS in the nab-paclitaxel group (P ¼ .15).
The prognostic significance of the NLR after 1 cycle, 2 cycles, and the end of treatment was analyzed further (Figure 2 ). In the eribulin group, no significant association was found between the PFS of the patients with an NLR < 3 and those with an NLR of ! 3 after 1 cycle (P ¼ .86; Figure 2A ), 2 cycles (P ¼ .24; Figure 2B ), and the last cycle (P ¼ .39; Figure 2C) . Thus, the NLR at baseline but not during treatment was associated with the PFS of patients treated with eribulin. We, therefore, performed a further analysis using the baseline data.
Subgroup Analyses of PFS According to Clinical Factors
The HRs and 95% CIs in subgroups of patients treated with eribulin are shown in Figure 3 . A consistently improved PFS for patients with an NLR of < 3 was observed in all subgroups, including those with a luminal (ER þ /HER2 À ; HR, 0.44; 95% CI, 0.19-0.96) or TN (HR, 0.11; 95% CI, 0.006-0.65) subtype and those with visceral disease (HR, 0.31; 95% CI, 0.13-0.66). Similarly, the PFS for patients with an NLR < 3 was better for those who had received previous anthracycline (HR, 0.34; 95% CI, 0.14-0.79), taxane (HR, 0.29; 95% CI, 0.13-0.60), de novo (HR, 0.32; 95% CI, 0.045-1.40), and recurrence (HR, 0.37; 95% CI, 0.16-0.79). In addition, this consistent association tended to be observed, irrespective of the number of previous chemotherapy regimens (HR, 0.37; 95% CI, 0.12-1.04 for 0-1 previous regimens; and HR, 0.50; 95% CI, 0.14-1.41 for 2-4 previous regimens).
Univariable and Multivariable Analyses for PFS Among Patients Treated With Eribulin
To confirm the significance of the NLR for PFS, univariable and multivariable analyses were performed (Table 2) . Five or more previous chemotherapy regimens (HR, 5.15; 95% CI, 1.87-13.11; P ¼ .0024) and a low NLR (HR, 0.36; 95% CI, 0.18-0.71; P ¼ .0028) were significantly associated with PFS. On multivariable analysis, both factors were significant and independent factors for PFS (HR, 4.34; 95% CI, 1.54-11.39; P ¼ .0070 for ! 5 previous chemotherapy regimens; and HR, 0.39; 95% CI, 0.18-0.78; P ¼ .0074 for a low NLR).
PFS of Patients Treated With Eribulin Because of Disease Progression With or Without New Metastatic Lesions
The relationship between NLR at baseline and the PFS of patients treated with eribulin was further analyzed according to the reasons for disease progression. The PFS of patients with progression without new metastatic lesions with an NLR of < 3 (median, 406 days; n ¼ 12) was significantly better than that of those with an NLR of ! 3 (median, 98 days; n ¼ 12; P ¼ .011; Figure 4A ). The PFS of patients with an NLR < 3 was better than that among those with an NLR of ! 3 in patients with progression with new metastatic lesions (median, 172.5 vs. 87.5 days; P ¼ .11; Figure 4B) ; however, the difference was not statistically significant.
Relationship Between NLR and Clinical Parameters
The PFS of patients stratified by the number of previous chemotherapy regimens is shown in Figure 5 . As expected, the PFS for the patients who had received ! 5 regimens (median, 68 days; n ¼ 7) was significantly worse than that of those who had received 0 to 1 (median, 237 days; n ¼ 28) or 2 to 4 (median, 162 days; n ¼ 24) regimens (P ¼ .0013).
The relationships between the NLRs and clinicopathologic characteristics are presented in Table 3 . The frequency of patients with an NLR < 3 significantly decreased as the number of patients who had received previous chemotherapy regimens increased (P ¼ .046). Of the 28 patients who had undergone 0 to 1 regimen of previous chemotherapy, 16 (57.1%) had an NLR of < 3. In contrast, 7 of 24 (29.2%) and only 1 of 7 (14.3%) patients had an NLR < 3 among those who had undergone 2 to 4 and ! 5 regimens of previous chemotherapy, respectively. No significant association was found between the NLR levels and other Low NLR and Improved PFS clinicopathologic factors, including menopausal status, ER and PR status, metastatic sites, and previous therapy with endocrines, anthracyclines, and taxanes.
Discussion
The results of the present study identified that MBC patients with a low NLR at baseline (before starting eribulin chemotherapy) had significantly improved PFS compared with patients with a high NLR. However, we did not observe any relationship between the NLR and patient outcome in the nab-paclitaxel group. The favorable outcomes among patients with a low NLR seemed to occur irrespective of ER status; previous use of anthracycline, taxane, or endocrine therapy; or the number of previous chemotherapy regimens. To the best of our knowledge, ours is the first study to demonstrate the usefulness of NLR in terms of treatment efficacy in the MBC setting.
Although detailed mechanisms of eribulin efficacy on OS rather than PFS are currently unknown, direct and indirect conversion from EMT to MET through vascular remodeling induced by eribulin has been speculated. [8] [9] [10] Ueda et al 10 reported that eribulin-induced reoxygenation resulted in the reduction of plasma concentrations of vascular endothelial growth factor and transforming growth factorb. 10 Because these factors are involved in EMT, this process might partly explain the reason for the improved OS with eribulin therapy, especially in patients with the TN subtype, which is reported at a high frequency in EMT. 13, 17 Nevertheless, it is reasonable to consider that reoxygenation by eribulin modulates the tumor microenvironment, resulting in various reprogramming, including that of the immune system. 18 In hypoxic microenvironments, acidic pH conditions impair lymphocyte cytotoxicity. 19 Furthermore, upregulation of hypoxiainducible factor-1a induces vascular endothelial growth factor expression, resulting in the suppression of CD8 þ T cells through FasL expression and apoptosis 20 or induction of programmed cell death ligand 1, which protects cancer cells from cytotoxic T lymphocytes in hypoxic microenvironments. 21 Thus, hypoxia-mediated escape from the adaptive immunity of breast cancer cells has been hypothesized. 
De novo or Recurrence
Abbreviations: Luminal ¼ estrogen receptor-positive/human epidermal growth factor receptor 2-negative; TNBC ¼ estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor 2-negative.
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Because eribulin improves the unfavorable hypoxic microenvironment, this effect seems to recover or enhance the immune reaction against breast cancer cells. If eribulin's efficacy is generated by modulating the immune reaction, this mechanism might play a role in the OS resulting from eribulin therapy. Kashiwagi et al 13 reported
significantly better PFS and OS for patients with high TILs compared with those with low TILs in the TN breast cancer subset among patients receiving eribulin. Our data further support a possible connection between eribulin treatment and immunoreactions. In contrast to TILs, which represent the local immunoreaction against Low NLR and Improved PFS breast cancer cells, the NLR is an indicator of the systemic immunoreaction. A meta-analysis of 8563 breast cancer patients from 15 studies demonstrated that an NLR greater than the cutoff was significantly associated with worse OS (HR, 2.56; 95% CI, 1.96-3.35; P < .001) and disease-free survival (HR, 1.74; 95% CI, 1.47-2.07; P < .001). 15 The amount of neutrophils in cancer patients reflect cancer-associated inflammation, which enhances the metastatic potential mediated through interleukin-8. 22 In contrast, lymphocyte infiltration of the tumor has been established as an indicator of anticancer immunity. 23 These results indicate that a low NLR reflects an enhanced immunoreaction against breast cancer. In contrast to early-stage breast cancer, the significance of the NLR as a prognostic indicator in the metastatic setting has not yet been reported, except for the study by Iwase et al, 16 which demonstrated that a higher NLR at recurrence was significantly associated with worse OS after recurrence. Their findings might support the usefulness of the NLR as a prognostic indicator, not only for early-stage breast cancer, but also for MBC. Although the prognostic significance of NLR has been established, the predictive usefulness of the NLR for the efficacy of chemotherapy remains controversial. Chen et al 24 reported that patients with a low NLR had significantly greater pathologic complete response (pCR) rates compared with patients with a higher NLR who had undergone neoadjuvant chemotherapy (24.5% vs. 14.3%; P < .05). Similarly, Asano et al 25 reported a greater pCR rate for patients with a low NLR who had received neoadjuvant chemotherapy. In contrast to these results, however, no significant association between the NLR and pCR rate has been reported. 26, 27 Thus, the predictive significance of the NLR in breast cancer remains unknown. The significant association between the NLR and PFS in MBC patients treated with eribulin, but not with nab-paclitaxel, suggests that the NLR might be useful, not as a prognostic indicator but, rather, as a predictor of eribulin efficacy. However, this finding should not be considered conclusive because of the small number of participants in the present study. This discrepant result between eribulin and nab-paclitaxel might be explained through the different actions induced by these drugs and that nab-paclitaxel is unlikely to modulate immunoreaction as the mechanism of its efficacy. The PFS for patients treated with eribulin, among those who had received ! 5 previous chemotherapy regimens was significantly worse than the PFS for the patients in the other groups ( Figure 5 ). In this subset, only 1 patient (14.3%) had a low NLR (Table 3) . In contrast, 16 of the 28 patients (57.1%) who had received 0 to 1 previous chemotherapy regimen had a low NLR. Because patients with a high NLR had undergone a greater number of previous chemotherapy regimens, it is likely that the poor PFS for the patients with a high NLR resulted from such extensive treatment. However, we have confirmed that the favorable PFS for the patients with a low NLR was obtained, irrespective of the number of previous chemotherapy regimens ( Figure 3 ) and both the NLR and the number of previous chemotherapy regimens were significant and independent factors for PFS (Table 2) . Accordingly, we believe that not only the background of patients' previous chemotherapy, but also the NLR was associated with the PFS for patients treated with eribulin. Because it has been previously reported that the development of new metastases in patients is an indicator of a poorer prognosis compared with that of patients with disease progression without new metastases, 28 we compared the PFS between patients with a low and high NLR according to the presentation of new lesions (ie, with or without new lesions). A favorable PFS for patients with a low NLR was found among the patients without new lesions (Figure 4 ). Although the mechanism is currently unknown, the benefit of the treatment efficacy of eribulin might be realized in breast cancer cases with a low NLR and a low potential for metastasis. These findings suggest that eribulin offers potential benefit for patients with sustained immunity, as indicated by a low NLR. Eribulin might provide few benefits for patients with low immunity (indicated by a high NLR). Because neutrophils and lymphocytes are always measured in daily clinical practice during chemotherapy, we can easily access NLR data without additional examinations. The NLR is superior to TILs for evaluating host immunity because the NLR is associated with PFS, irrespective of ER status. However, Kashiwagi et al 13 reported that TILs are restricted in the TN patient subset. Although the NLR cutoff has ranged from 1.9 to 5.0 in previous studies of, mostly, early-stage breast cancer, the median cutoff was 3.0, 15 the same cutoff used in a study that analyzed the prognosis of MBC. 16 Because of their results, we also used a cutoff of 3. Nevertheless, the optimal NLR cutoff for predicting eribulin efficacy remains unknown. This issue requires investigation in future prospective studies of larger numbers of patients.
Conclusion
The results of the present study have demonstrated that the NLR at baseline might be a significant indicator for eribulin treatment efficacy but not that of nab-paclitaxel. This significant association was present irrespective of ER status, previous anthracycline or endocrine use, and the number of previous chemotherapy regimens. These findings might contribute to a better understanding of the mechanisms of action of eribulin and might be useful for selecting patients who will benefit from treatment with eribulin.
Clinical Practice Points
Eribulin and nab-paclitaxel are useful and effective chemotherapy agents for locally advanced or MBC.
Although eribulin results in the potential conversion from mesenchymal to epithelial phenotypes directly and indirectly by mediating reoxygenation, the detailed mechanisms of action of this drug remain unknown. We investigated the usefulness of the NLR, a reportedly significant prognostic factor for early-stage breast cancer, in terms of the efficacy of eribulin treatment for MBC. The NLR at baseline was significantly associated with improved outcomes for patients who received eribulin but not for those who received nab-paclitaxel. Because NLR reflects the systemic immunity in patients, the treatment efficacy of eribulin might thus be mediated, in part, by an immunoreaction against breast cancer.
We believe our results contribute to a better understanding of the mechanisms of action of eribulin and will be useful in selecting patients who could benefit from eribulin treatment. 
